



Prior Authorization Approval Criteria

Strattera (atomoxetine)

Generic name: atomoxetine

Brand name: Strattera

Medication class: Norepinephrine reuptake inhibitor, non-CNS stimulant

FDA approved uses: ADHD in children and adults

Usual doses: 60 mg/day (maximum 120 mg/day)
Dosing frequency once daily or twice daily

Duration of therapy: Indefinite

Criteria for use: *(bullet points below are all inclusive unless otherwise noted)*

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Patients with clinically defined ADHD
- Failed/intolerant to generic methylphenidate
- Failed/intolerant to mixed amphetamine salts

OR

- Past history of drug or alcohol abuse.

Precautions:

- Patients with known heart disease or hypertension should avoid use.
- Patients with decreased appetites, or decreased growth rates should use with caution (monitor regularly).
- Adult patients with BPH should use with caution.

P&T Approval: _____ Date: _____
Adopted: 11/18/04